- Home
- PETZ vs TENX Comparison
PETZ vs TENX Comparison
Compare PETZ & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- TENX
- Stock Information
- Founded
- PETZ 2002
- TENX 1967
- Country
- PETZ China
- TENX United States
- Employees
- PETZ N/A
- TENX N/A
- Industry
- PETZ Steel/Iron Ore
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- TENX Health Care
- Exchange
- PETZ Nasdaq
- TENX Nasdaq
- Market Cap
- PETZ 13.1M
- TENX 13.9M
- IPO Year
- PETZ 2017
- TENX N/A
- Fundamental
- Price
- PETZ $1.16
- TENX $3.96
- Analyst Decision
- PETZ
- TENX Strong Buy
- Analyst Count
- PETZ 0
- TENX 1
- Target Price
- PETZ N/A
- TENX $30.00
- AVG Volume (30 Days)
- PETZ 9.7K
- TENX 45.8K
- Earning Date
- PETZ 10-29-2024
- TENX 11-11-2024
- Dividend Yield
- PETZ N/A
- TENX N/A
- EPS Growth
- PETZ N/A
- TENX N/A
- EPS
- PETZ N/A
- TENX N/A
- Revenue
- PETZ $3,175,809.00
- TENX N/A
- Revenue This Year
- PETZ N/A
- TENX N/A
- Revenue Next Year
- PETZ N/A
- TENX N/A
- P/E Ratio
- PETZ N/A
- TENX N/A
- Revenue Growth
- PETZ 2.49
- TENX N/A
- 52 Week Low
- PETZ $0.89
- TENX $2.77
- 52 Week High
- PETZ $1.74
- TENX $61.20
- Technical
- Relative Strength Index (RSI)
- PETZ 45.74
- TENX 50.23
- Support Level
- PETZ $1.10
- TENX $3.53
- Resistance Level
- PETZ $1.21
- TENX $3.98
- Average True Range (ATR)
- PETZ 0.06
- TENX 0.19
- MACD
- PETZ -0.00
- TENX -0.05
- Stochastic Oscillator
- PETZ 31.58
- TENX 44.44
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.